Showing 1721-1730 of 3038 results for "".
- NovaBay Pharmaceuticals Enters Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova Allografthttps://modernod.com/news/novabay-pharmaceuticals-enters-agreement-with-biostem-technologies-to-commercialize-amniotic-tissue-allograft-as-avenova-allograft/2481821/NovaBay Pharmaceuticals and BioStem Technologies announced an agreement under which NovaBay has been granted the right to commercialize BioStem Technologies’ Amniotic Tissue Allograft, which is intended for use as a protective covering during the repair of ocular surfaces. Fi
- Opthea Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302https://modernod.com/news/opthea-announces-sozinibercept-as-the-nonproprietary-drug-name-for-opt-302/2481747/Opthea announced that the American Medical Association’s United States Adopted Names (USAN) Council has approved the nonproprietary drug name “sozinibercept” for the company’s lead biologic drug candidate, OPT-302. Sozinibercept (OPT-302) is
- Harrow Acquires US and Canadian Commercial Rights to Dry Eye Drug Vevye from Novaliqhttps://modernod.com/news/harrow-acquires-us-and-canadian-commercial-rights-to-vevye-cyclosporine-ophthalmic-solution-01-from-novaliq/2481734/Harrow has entered the prescription dry eye disease treatment business as it announced a deal to acquire the US and Canadian commercial rights to Vevye (cyclosporine ophthalmic solution 0.1%) from Novaliq. Under terms of the deal, Harrow will make an initi
- Caeregen Therapeutics Receives $1.4 Million Phase 2 SBIR Grant from NIH/NEI to Advance Development of Noregen for Retinal Diseaseshttps://modernod.com/news/caeregen-therapeutics-receives-14-million-phase-2-sbir-grant-from-nihnei-to-advance-development-of-regenerative-medicine-clinical-candidate-ctr-107-noregen-for-retinal-diseases/2481729/Caeregen Therapeutics announced that it has been awarded a $1.4 million phase 2 Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) and National Eye Institute (NEI) to advance the development of CTR-107 (Noregen), a regenerative therapeutic for the treatme
- Bausch + Lomb to Acquire Xiidra from Novartishttps://modernod.com/news/bausch-lomb-will-acquire-xiidra/2481704/Bausch + Lomb announced it has entered into a definitive agreement with Novartis under which Bausch + Lomb will acquire dry eye drug Xiidra (lifitegrast ophthalmic solution) 5%. Xiidra is a non-steroid eye drop specifically approved to treat the signs and symptoms of dry eye disease (DE
- Study Uncovers Novel Synaptic Intricacies Inside the Retinahttps://modernod.com/news/study-uncovers-novel-synaptic-intricacies-inside-the-retina/2481687/A Northwestern Medicine study has uncovered novel cellular mechanisms within the retina, findings that researchers say could help advance the development of targeted therapeutics for diseases and conditions impacting vision. The findings were
- Senju Pharmaceutical and Novaliq Enter Into License Agreement For NOV03 For the Treatment of Dry Eye Disease in Japanhttps://modernod.com/news/senju-pharmaceutical-and-novaliq-enter-into-license-agreement-for-nov03-for-the-treatment-of-dry-eye-disease-in-japan/2481671/Senju Pharmaceutical and Novaliq have enteed into a license agreement for NOV03 (perfluorohexyloctane ophthalmic solution) for the treatment of dry eye disease in Japan. Financial terms of the deal were not disclosed. Senju Pharmaceutical acquires the rights in Japa
- FDA Clears CorNeat EverPatch, World's First Non-Degradable, Synthetic Tissue Substitute for Ophthalmic Surgeryhttps://modernod.com/news/fda-clears-corneat-everpatch-worlds-first-non-degradable-synthetic-tissue-substitute-for-ophthalmic-surgery/2481668/The FDA has granted 510(k) clearance to CorNeat Vision's EverPatch, which the company describes as the first synthetic, non-degradable tissue-integrating matrix for use in ophthalmic surgeries. It is composed of a non-woven, polymer matrix which integrates with surrounding tissue an
- FDA Approves Novaliq's Cyclosporine Eye Drop Vevye for Treatment of Dry Eye Diseasehttps://modernod.com/news/novaliq-announces-fda-approval-of-vevye-for-the-treatment-of-the-signs-and-symptoms-of-dry-eye-disease/2481664/Just 3 weeks after receiving FDA approval for dry eye drug Miebo, Novaliq has received FDA approval for Vevye (cyclosporine ophthalmic solution; formerly known as CyclASol) 0.1% for the treatment of the signs and symptoms of dry eye disease. Novaliq says Vevye is the first and only
- EyePoint Pharmaceuticals Completes Enrollment in Phase 2 PAVIA Clinical Trial of EYP-1901 in Non-Proliferative Diabetic Retinopathyhttps://modernod.com/news/eyepoint-pharmaceuticals-completes-enrollment-in-phase-2-pavia-clinical-trial-of-eyp-1901-in-non-proliferative-diabetic-retinopathy/2481648/EyePoint Pharmaceuticals announced it has completed enrollment in the phase 2 PAVIA clinical trial evaluating EYP-1901 as a potential 9-month treatment for moderate to severe non-proliferative diabetic retinopathy (NPDR). “We are delighted to report the completion of enrollment in